


Clinical Trial for Mild Cognitive Impairment

Sutter Institute for Medical Research (SIMR) and **Sutter Neuroscience Institute** are conducting a randomized, double-blind, placebo controlled study of **mild cognitive impairment (MCI)**.

This study will investigate the potential treatment effects of IVIG (intravenous immunoglobulin) to target early Alzheimer's pathology in persons with MCI. Serial MRI brain imaging and cognitive testing will be conducted over approximately 2 years to assess for reduction of rate of brain atrophy or reduction of conversion to dementia due to Alzheimer disease in the IVIG group compared to placebo.



Inclusion criteria:

- 50 to 84 years old.
- Subjective memory complaints or any sign of memory dysfunction.
- MMSE 24 to 30.
- Do NOT meet criteria for dementia (i.e., no functional impairment).
- No contraindication for MRI.
- No history of cholinesterase-inhibitors, memantine, or Axona for cognitive enhancement within 90 prior to screening.

For more information about this trial, please contact:

Shawn Kile, MD or William Au, MD

Study Coordinator: Tammy Donnel, CCRP

(916) 453-5994